Melief CJM - Search Results

1

Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.

Speetjens FM, Welters MJP, Slingerland M, van Poelgeest MIE, de Vos van Steenwijk PJ, Roozen I, Boekestijn S, Loof NM, Zom GG, Valentijn ARPM, Krebber WJ, Meeuwenoord NJ, Janssen CAH, Melief CJM, van der Marel GA, Filippov DV, van der Burg SH, Gelderblom H, Ossendorp F. Speetjens FM, et al. Among authors: melief cjm. J Immunother Cancer. 2022 Oct;10(10):e005016. doi: 10.1136/jitc-2022-005016. J Immunother Cancer. 2022. PMID: 36261215 Free PMC article. Clinical Trial.

2

Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.

Nijman HW, Houbiers JG, van der Burg SH, Vierboom MP, Kenemans P, Kast WM, Melief CJ. Nijman HW, et al. J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):121-6. J Immunother Emphasis Tumor Immunol. 1993. PMID: 7506574

3

Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase.

van der Burg SH, Klein MR, van de Velde CJ, Kast WM, Miedema F, Melief CJ. van der Burg SH, et al. AIDS. 1995 Feb;9(2):121-7. AIDS. 1995. PMID: 7536421

4

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors.

Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, Melief CJ, Kast WM. Feltkamp MC, et al. Eur J Immunol. 1995 Sep;25(9):2638-42. doi: 10.1002/eji.1830250935. Eur J Immunol. 1995. PMID: 7589138

5

Antibodies against p53 are associated with poor prognosis of colorectal cancer.

Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, Melief CJ. Houbiers JG, et al. Br J Cancer. 1995 Sep;72(3):637-41. doi: 10.1038/bjc.1995.386. Br J Cancer. 1995. PMID: 7669574 Free PMC article.

6

Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes.

Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM. Nijman HW, et al. Eur J Immunol. 1993 Jun;23(6):1215-9. doi: 10.1002/eji.1830230603. Eur J Immunol. 1993. PMID: 7684681

7

Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG).

Ballieux BE, van der Burg SH, Hagen EC, van der Woude FJ, Melief CJ, Daha MR. Ballieux BE, et al. Clin Exp Immunol. 1995 May;100(2):186-93. doi: 10.1111/j.1365-2249.1995.tb03651.x. Clin Exp Immunol. 1995. PMID: 7743653 Free PMC article.

8

Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.

Melief CJ, Kast WM. Melief CJ, et al. Ciba Found Symp. 1994;187:97-104; discussion 104-12. doi: 10.1002/9780470514672.ch7. Ciba Found Symp. 1994. PMID: 7796678 Review.

9

p53, a potential target for tumor-directed T cells.

Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ. Nijman HW, et al. Immunol Lett. 1994 May;40(2):171-8. doi: 10.1016/0165-2478(94)90189-9. Immunol Lett. 1994. PMID: 8088874

10

Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes.

Sijts AJ, Ossendorp F, Mengedé EA, van den Elsen PJ, Melief CJ. Sijts AJ, et al. J Immunol. 1994 Jan 1;152(1):106-16. J Immunol. 1994. PMID: 8254184

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

543 results

Search Page